$XNCR

GUSTAFSON KURT A sold $67K of XNCR

GUSTAFSON KURT A sold 5,474 shares of Xencor Inc (XNCR) at $12.31 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GUSTAFSON KURT A
Published Jun 17, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XNCR
Neutral
medium confidence
Mentioned
$XNCR
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XNCRNeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider activity datapoint, but the 10b5-1 structure generally reduces interpretability as a new fundamental signal.

02

Market read

Traders may monitor for follow-on insider activity, but this specific Form 4 is unlikely to drive a major repricing by itself.

03

What to watch

The filing doesn’t reveal whether other insiders or institutions are changing positions, so broader ownership/flow context could matter more than this single sale.

Relevance 2/10Novelty 6/10Timing: Filed June 17, 2026; sale executed June 15, 2026.

Background

The article is an SEC Form 4 insider transaction disclosure for Xencor, showing a director’s sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$XNCRNeutralMedium confidence
Context

Xencor disclosed a director open-market sale of 5,474 shares at $12.31 on a Rule 10b5-1 plan, totaling $67,384.94.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment-driven than fundamentals.

Evidence & confidence

The filing is a primary Form 4, but the transaction is explicitly under a pre-arranged 10b5-1 plan and the dollar amount is modest versus typical market moves.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations; traders may discount it.

Key entities

  • Xencor Inc

    Issuer of the securities sold by a director under a Rule 10b5-1 plan.

  • Gustafson Kurt A

    Director who sold 5,474 shares in an open-market transaction.

Related articles

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xncr-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indica

$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

$XNCRMedAI 8/10

Xencor, Inc.: Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter

Xencor (NASDAQ:XNCR) said it reached a settlement with Alexion to resolve a U.S. Ultomiris (ravulizumab-cwvz) royalty dispute. Under the agreement, Xencor will receive $105 million in two $52.5 million payments, expected in Aug. 2026 and one year later. Alexion will owe no further U.S. royalties, while ex-U.S. royalties continue. Xencor expects cash through 2028.

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. xncr-20260729 FALSE 0001326732 0001326732 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 8-K ___________________________________________________ CURRENT REPORT Pursuant to Sect